U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07045311) titled 'JS207 Combination Therapy in Triple-negative Breast Cancer' on June 23.
Brief Summary: This is an open-label, multi-center, phase II clinical study to preliminarily evaluate the efficacy and safety of JS207 combined with 9MW2821 or albumin paclitaxel as first-line therapy in patients with recurrent or metastatic TNBC.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Triple-negative Breast Cancer
Intervention:
DRUG: JS207 in combination with 9MW2821
JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), 9MW2821 will be administered intravenously at a dose of 1.25 mg/kg (D1 and D8, Q3W)
DRUG: J...